Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aramchol Versus Placebo in the Treatment of HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy: A Randomized, Double-blinded, Allocation-concealed, Placebo-controlled Clinical Trial

Next Previous
Trial Profile

Aramchol Versus Placebo in the Treatment of HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy: A Randomized, Double-blinded, Allocation-concealed, Placebo-controlled Clinical Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icomidocholic acid (Primary)
  • Indications Lipodystrophy; Non-alcoholic fatty liver disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ARRIVE
  • Sponsors Galmed Pharmaceuticals

Most Recent Events

  • 11 Jun 2018 Status changed from recruiting to completed.
  • 14 Feb 2018 Primary endpoint (Efficacy of Aramchol 600 mg vs. placebo in improving hepatic steatosis in patients with HIV-associated NAFLD) has not been met.
  • 27 Nov 2017 According to a Galmed Pharmaceuticals media release, foundations of the ARRIVE and ARREST clinical studies will be presented at at the 22nd biennial HEP DART meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top